NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that...
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the...
SIGA Technologies` Tecovirimat (tecovirimat) Receives Approval in Europe
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced receipt of approximately $16 million of international procurement orders for oral TPOXX® (tecovirimat) in August and early September, including an approximate $10 million order by the European Commission, through funds from the European Health Emergency Preparedness and Response Authority (HERA) and implemented via rescEU, and approximately $6 million of orders from two countries in the Asia Pacific region, one of which is a new customer.
Less than a month after streamlining the process to endorse the lone treatment for monkeypox, the FDA is now urging doctors to be “judicious” in their prescribing of Siga’s tecovirimat (Tpoxx).
The National Institute for Health and Care Research (NIHR) has commissioned and funded a clinical trial analysing a potential therapy of SIGA Technologies, tecovirimat (TPOXXÒ), to treat patients diagnosed with monkeypox.
The first participant enrolled on Friday in the PLATINUM (Placebo-controlled randomized trial of tecovirimat in nonhospitalised monkeypox patients) trial, building off animal model successes that led to FDA and UK approvals, and follows the NIH’s National Institute of Allergy and Infectious Diseases announcement that it’s launching a similar trial in the US next week.
- Approximately $26 Million of Orders Received from Canada underExisting Procurement Contracts –- Approximately $2 Million of Orders Received from Two New Jurisdictions - NEW YORK, July 12,...
NEW YORK, July 08, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced...